source
- Intercept's next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharmaIntercept Pharmaceuticals' attempt at creating a next-generation FXR agonist for certain forms of liver inflammation appears to have ended. The drug developer's INT-787 showed "no clear evidence of…Endpoints · 2mo ago↗ source
- Pfizer's Albert Bourla says he has no mega-merger plansThe most candid man in pharma strikes again. When asked on Tuesday’s earnings call whether Pfizer would consider a “transformative M&A” deal in the near or medium term, CEO Albert Bourla said it wo…Endpoints · 2mo ago↗ source
- BioNTech to scale down manufacturing, over 1,800 jobs on the lineBioNTech is making big cuts to its manufacturing footprint. The German company said in its first-quarter earnings release that up to 1,860 manufacturing staff could be impacted by its planned downs…